The Incidence and Risk Factors of Central Nervous System Adverse Events of Lorlatinib in Patients with ALK-positive Advanced Non-small Cell Lung Cancer: a Real-world Study

Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinoma

NCT06858410 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3

Lorlatinib in ROS1+ NSCLC With Brain Metastasis

NCT07083687 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Explore the Mechanisms Underlying Disease Resistance and Potential Primary Resistance Mechanism of Induction Therapy Lorlatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Positive Mutation Revealed by Single-cell RNA Sequencing and Spatial Transcriptomics

NCT06893354 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4

Resistance Mechanisms and Sequential Treatment Strategies Following First-Line Lorlatinib in ALK-Positive NSCLC

NCT06904547 ·Status: NOT_YET_RECRUITING

Study to Evaluate Clinical Real World Outcomes of Lorlatinib After Alectinib in ALK-Positive NSCLC Japanese Patients

NCT04979988 ·Status: COMPLETED

A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled

NCT06282991 ·Status: COMPLETED

Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases

NCT06282874 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4

A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China

NCT03909971 ·Status: COMPLETED ·Phase: PHASE2

Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC Patients

NCT04127110 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

LORLATINIB-related HYPERLIPIDEMIA in ALK+ Non-Small Cell Lung Cancer

NCT06876675 ·Status: ENROLLING_BY_INVITATION

Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer ALK Positive or ROS1 Positive

NCT03178071 ·Status: NO_LONGER_AVAILABLE

A Retrospective Study of the Efficacy and Safety of Lolatinib in ALK+ NSCLC Patients With Brain or Meningeal Metastasis

NCT06410040 ·Status: ACTIVE_NOT_RECRUITING

A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer

NCT05297890 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India

NCT04541706 ·Status: COMPLETED ·Phase: PHASE4

Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer

NCT04111705 ·Status: COMPLETED ·Phase: PHASE2

Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements

NCT05987644 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Clinical Study of First-line Treatment of Small Cell Lung Cancer (SCLC) With Anlotinib Hydrochloride

NCT03890055 ·Status: UNKNOWN ·Phase: PHASE4

Exosomes Detection for the Prediction of the Efficacy and Adverse Reactions of Anlotinib in Patients With Advanced NSCLC

NCT05218759 ·Status: NOT_YET_RECRUITING ·Phase: NA

Study of Safety, Efficacy and Pharmacokinetics of CT-707 in Patients With ALK-positive Non-small Cell Lung Cancer

NCT02695550 ·Status: UNKNOWN ·Phase: PHASE1

Study of Lorlatinib in ROS1 Rearranged NSCLC

NCT03612154 ·Status: UNKNOWN ·Phase: PHASE2

A Study of Lobaplatin/Etoposide With or Without Anlotinib Maintenance Therapy in Patients With ES-SCLC

NCT03700359 ·Status: UNKNOWN ·Phase: PHASE2

A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Following 4 Cycles of Platinum-based Chemotherapy Without Disease Progression

NCT01230710 ·Status: COMPLETED ·Phase: PHASE4

Erlotinib Combined With Radiotherapy in Patients With Non-resectable Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)

NCT01091376 ·Status: UNKNOWN ·Phase: PHASE2

Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer

NCT04665856 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC)

NCT02013219 ·Status: COMPLETED ·Phase: PHASE1